Almost every synthetic peptide arrives as a salt, and which salt it is changes how much peptide is in the vial. Trifluoroacetate is the default because of how purification works, not because anyone chose it for the molecule. Acetate is the common alternative. The difference matters for mass accounting and for any experiment where the counter-ion is not inert — and TFA is not inert in several situations where it is routinely assumed to be.
Why there is a counter-ion at all
A peptide carrying basic residues — lysine, arginine, histidine, plus the free N-terminus — is positively charged at the pH it is purified and lyophilised at. Charge has to be balanced, so every positive site pairs with a negative counter-ion. The peptide cannot be isolated as a neutral free base; it comes out of the process as a salt.
Which salt depends on the mobile phase. Reversed-phase HPLC of peptides is run with trifluoroacetic acid as an ion-pairing additive, because it sharpens peaks and improves resolution better than the alternatives. TFA is therefore present throughout purification, and it is what pairs with the peptide when the fractions are dried. The counter-ion is an inherited property of the method.
How much of the vial is counter-ion?
More than most people expect, and it scales with the number of basic sites. Each one carries a counter-ion, so a peptide with several basic residues can hold a counter-ion burden in the range of 5–20% of total mass. TFA is the heavier of the two at 114 g/mol against acetate's 60, so a TFA salt carries more mass per site than an acetate salt of the same peptide. That mass is part of what the label weighs and none of it is peptide — one of the components in what a 5 mg vial actually contains.
Does the salt form change the concentration I calculate?
It changes the amount of peptide behind the number, which amounts to the same practical problem. Concentration computed from the label mass assumes the powder is peptide; the fraction that is counter-ion, water and impurity is not. Two vials of the same sequence at the same label mass, one a TFA salt and one an acetate salt, contain different quantities of peptide. The figure that resolves this is net peptide content on the certificate, and calculating from label mass without it introduces an error that is systematic rather than random — it always overstates, and always in a direction that flatters the material.
Where TFA stops being a bystander
For many uses the counter-ion is genuinely inconsequential. In four situations it is not.
| Situation | What TFA does |
|---|---|
| Cell-based assays | Cytotoxic in the range residual TFA can reach; effects attributed to the peptide may be the salt |
| Circular dichroism | Absorbs strongly in the far UV, exactly where the peptide backbone signal sits |
| Infrared spectroscopy | A carbonyl stretch near 1673 cm⁻¹ overlaps the amide I band used for structure |
| Quantitative mass accounting | Heavier than acetate, so it consumes more of the label mass per basic site |
The first is the one that produces wrong conclusions rather than noisy data, because the failure looks like a result. Reduced viability from residual TFA is indistinguishable from reduced viability caused by the compound unless a control separates them.
Is TFA cytotoxic at the concentrations actually present?
It can be, and whether it is depends on the batch rather than on the compound. Residual TFA varies with how thoroughly the material was dried and how many basic sites it carries, and the sensitivity varies by cell line. The problem is that the concentration is rarely known: TFA content is not reported on most certificates. Where a cell-based readout matters, either an acetate salt or a vehicle control matched for TFA is the minimum, and the vehicle control is the one that also catches the case where the assumption about which salt was supplied is wrong.
How is a peptide converted to the acetate form?
By ion exchange, or by repeated lyophilisation from dilute acetic acid. Neither is free: both add handling steps, both cost some material, and neither removes TFA completely — the honest description is a substantial reduction rather than an elimination. That is why acetate salts are generally supplied at a higher price and often on request. It is also why "acetate salt" should be read as a statement about which ion predominates rather than a guarantee that no TFA is present.
Reading the certificate for it
Counter-ion identity and content sit in the group of figures that are frequently absent and occasionally decisive. A certificate reporting purity, identity and content, with no mention of the salt form, is not defective — it is simply silent on a question that matters for some work and not for others. The two things worth looking for are which salt the material is, and what proportion of the mass it accounts for. The general skill of matching a panel to the question it answers covers this case; the specific point is that silence here should be read as unknown rather than as absent.
Why is TFA used in purification if it causes these problems?
Because it works better than the alternatives at the job it is there for. TFA is a strong acid that ion-pairs efficiently with basic sites, suppresses unwanted interactions with residual silanols on the column, and produces sharper peaks and better resolution than acetate or formate. Switching the mobile phase to avoid the downstream problem degrades the separation that determines the purity figure itself. The counter-ion is a consequence of optimising purification, and converting afterwards is the standard answer precisely because purifying differently is the worse trade.
Does the counter-ion affect stability or solubility?
Both, modestly. Acetate is the weaker acid, so an acetate salt tends to give a slightly less acidic solution on reconstitution, which can matter for a sequence sensitive at low pH. Solubility differences are real but usually small compared with the effect of the sequence itself. Neither effect is typically the reason to choose one over the other — the assay-interference question decides it in almost every case, and stability is a secondary consideration rather than a deciding one.
All products referenced here are supplied for laboratory and research use only. They are not drugs, foods, supplements or cosmetics, and are not for human or veterinary use.
